The IsoFlux System enables somatic variant detection from circulating tumor cells (CTCs) obtained from a routine blood draw using the latest advances in Next-Generation Sequencing (NGS). The system enriches circulating tumor cells, or other rare circulating cells, from peripheral blood and prepares them for molecular analysis, including NGS, qPCR, FISH, and immunofluorescence. The resulting samples have the required tumor DNA content and purity to be used with the leading NGS content panels, ranging from 50 to 400 genes and thousands of variants.
GE analysis revealed a different deregulation pattern related to the EMT, NE and AR-related phenotypes in resistant CRPC-cells compared to parental cells. Docetaxel resistance was more associated to an EMT phenotype while cabazitaxel resistance to NE patterns. GE patterns in CTCs at post taxane-treatment showed a common upregulation of AR-related genes compared to pre-treatment collected samples. Moreover, most patients experienced upregulation of EMT and NE markers after treatment, which was more pronounced after docetaxel than cabazitaxel therapy.
Read the paper, discover more!